Respiratory Syncytial Virus (RSV) Diagnostics Global Market Report 2025

The respiratory syncytial virus (RSV) diagnostics market size has grown rapidly in recent years. It will grow from $1.01 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth during the historic period was driven by the increasing adoption of point-of-care diagnostics, government initiatives to enhance RSV diagnostics, the rising incidence of respiratory diseases in children, the growth of hospital-acquired infections, and the growing demand for non-invasive diagnostic methods.

The respiratory syncytial virus (RSV) diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The projected growth during the forecast period is driven by the increasing prevalence of respiratory syncytial virus (RSV) infections, rising awareness of RSV diagnostics, expanding healthcare infrastructure, growing global healthcare spending, and the aging population. Key trends include advancements in molecular diagnostic technologies, technological innovations in diagnostic devices, the adoption of rapid diagnostic tests (RDTs), the expansion of diagnostic test portfolios by companies, and progress in genetic and proteomic diagnostics.

The increasing prevalence of respiratory diseases is expected to drive the demand for respiratory syncytial virus (RSV) diagnostics. Respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and respiratory infections, are becoming more widespread due to factors such as air pollution, smoking, climate change, urbanization, and the rising incidence of chronic conditions. RSV diagnostics play a crucial role in identifying infections accurately and in a timely manner, enabling appropriate treatment, management, and prevention of severe complications, particularly in vulnerable populations. For instance, in November 2024, the Australian Institute of Health and Welfare reported that an estimated 2.8 million people (11% of the population) in Australia were living with asthma in 2022. Asthma accounted for 2.5% of the total disease burden and 35% of the burden from all respiratory conditions in 2023, with 467 asthma-related deaths in 2022. Therefore, the rising prevalence of respiratory diseases is fueling growth in the RSV diagnostics market.

Leading companies in the RSV diagnostics market are focusing on innovative multi-virus diagnostic testing to enhance efficiency and accuracy. Multi-virus diagnostic testing enables the simultaneous detection of multiple respiratory viruses, such as RSV, influenza, and COVID-19, from a single patient sample. For example, in January 2023, Sonora Quest Laboratories, a US-based clinical laboratory testing company, introduced a new molecular diagnostic test that detects COVID-19, RSV, and influenza using a single sample. By combining these tests, the process is streamlined, reducing the need for multiple samples and enabling faster, more comprehensive diagnoses. This approach allows healthcare providers to make quicker treatment decisions and helps prevent the spread of these viruses.

In November 2023, Medix Biochemica, a Finland-based biotechnology company, acquired ViroStat LLC for an undisclosed amount. This acquisition expands Medix Biochemica’s infectious disease diagnostic portfolio by integrating ViroStat's expertise in monoclonal antibodies and antigen detection kits for RSV testing. ViroStat LLC, a US-based company, specializes in developing diagnostic solutions for various infectious diseases, including RSV, further strengthening Medix Biochemica’s position in the RSV diagnostics market.

Major players in the respiratory syncytial virus (RSV) diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Becton, Dickinson, and Company, Quest Diagnostics Incorporated, Hologic Inc., BIOMÉRIEUX SA, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Acon Laboratories Inc., Cepheid Inc., Meridian Bioscience Inc., Seegene Inc., LumiraDx Ltd., Sekisui Diagnostics Ltd., Boditech Med Inc., Trinity Biotech plc, R-Biopharm AG, GeneTex Inc., Creative Diagnostics, Certest Biotec S.L., Clarity Diagnostics LLC, Genes 2Me LLP, Coris BioConcept S.A.

North America was the largest region in the respiratory syncytial virus (RSV) diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory syncytial virus (RSV) diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Respiratory Syncytial Virus (RSV) Diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Respiratory syncytial virus (RSV) diagnostics encompass the tests and methods used to detect RSV in patients, typically through respiratory samples such as nasal or throat swabs. These diagnostics are essential for identifying RSV infections, which can cause respiratory illnesses in infants, young children, and the elderly, aiding in appropriate treatment and disease management.

The primary types of RSV diagnostic products include kits and assays, instruments, reagents, and others. Kits and assays are pre-packaged sets containing reagents, materials, and instructions for conducting specific diagnostic tests. Various technologies are used for RSV detection, including molecular diagnostics, immunoassays, and rapid antigen detection tests. Sample types include nasal swabs, throat swabs, and bronchoalveolar lavage. These diagnostics are utilized in hospitals, diagnostic laboratories, home care settings, and other healthcare environments.

The respiratory syncytial virus (RSV) diagnostics market research report is one of a series of new reports that provides respiratory syncytial virus (RSV) diagnostics market statistics, including respiratory syncytial virus (RSV) diagnostics industry global market size, regional shares, competitors with a respiratory syncytial virus (RSV) diagnostics market share, detailed respiratory syncytial virus (RSV) diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (RSV) diagnostics industry. This respiratory syncytial virus (RSV) diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus (RSV) diagnostics market consists of revenues earned by entities by providing services such as diagnostic consultation, research and development support, training and technical support. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) diagnostics market also includes sales of immunofluorescence test kits, multiplex panels, sample collection devices and automated testing instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.